FBXW7 tumor suppressor regulation by dualspecificity tyrosine-regulated kinase 2.


Journal

Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092

Informations de publication

Date de publication:
18 03 2023
Historique:
received: 06 07 2022
accepted: 03 03 2023
revised: 28 02 2023
entrez: 19 3 2023
pubmed: 20 3 2023
medline: 22 3 2023
Statut: epublish

Résumé

FBXW7 is a member of the F-box protein family, which functions as the substrate recognition component of the SCF E3 ubiquitin ligase. FBXW7 is a main tumor suppressor due to its ability to control proteasome-mediated degradation of several oncoproteins such as c-Jun, c-Myc, Cyclin E1, mTOR, and Notch1-IC. FBXW7 inactivation in human cancers results from a somatic mutation or downregulation of its protein levels. This work describes a novel regulatory mechanism for FBXW7 dependent on the serine/threonine protein kinase DYRK2. We show that DYRK2 interacts with and phosphorylates FBXW7 resulting in its proteasome-mediated degradation. DYRK2-dependent FBXW7 destabilization is independent of its ubiquitin ligase activity. The functional analysis demonstrates the existence of DYRK2-dependent regulatory mechanisms for key FBXW7 substrates. Finally, we provide evidence indicating that DYRK2-dependent regulation of FBXW7 protein accumulation contributes to cytotoxic effects in response to chemotherapy agents such as Doxorubicin or Paclitaxel in colorectal cancer cell lines and to BET inhibitors in T-cell acute lymphoblastic leukemia cell lines. Altogether, this work reveals a new regulatory axis, DYRK2/FBXW7, which provides an understanding of the role of these two proteins in tumor progression and DNA damage responses.

Identifiants

pubmed: 36934104
doi: 10.1038/s41419-023-05724-0
pii: 10.1038/s41419-023-05724-0
pmc: PMC10024693
doi:

Substances chimiques

Cell Cycle Proteins 0
F-Box-WD Repeat-Containing Protein 7 0
FBXW7 protein, human 0
Proteasome Endopeptidase Complex EC 3.4.25.1
Ubiquitin-Protein Ligases EC 2.3.2.27
Protein Serine-Threonine Kinases EC 2.7.11.1
Protein-Tyrosine Kinases EC 2.7.10.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

202

Informations de copyright

© 2023. The Author(s).

Références

Cell Res. 2015 May;25(5):561-73
pubmed: 25753158
Nat Rev Cancer. 2014 Apr;14(4):233-47
pubmed: 24658274
Cell Rep. 2018 Apr 3;23(1):213-226.e3
pubmed: 29617661
Cancer Lett. 2018 Apr 10;419:75-83
pubmed: 29355657
Nucleic Acids Res. 2017 Jul 27;45(13):7807-7824
pubmed: 28549174
Cancer Cell. 2014 Oct 13;26(4):455-64
pubmed: 25314076
Cell Death Dis. 2019 Aug 2;10(8):579
pubmed: 31371703
Mol Cell. 2012 Jun 29;46(6):771-83
pubmed: 22608923
Oncol Lett. 2020 Aug;20(2):1526-1534
pubmed: 32724394
Cell Mol Life Sci. 2020 Dec;77(23):4747-4763
pubmed: 32462403
J Biol Chem. 2019 Sep 6;294(36):13224-13232
pubmed: 31346036
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
Mol Cancer. 2020 Sep 9;19(1):139
pubmed: 32907612
Cell. 2008 May 2;133(3):537-48
pubmed: 18455992
FASEB J. 2011 Feb;25(2):449-62
pubmed: 21048044
Pathol Res Pract. 2016 Mar;212(3):162-70
pubmed: 26804244
Nature. 2011 Mar 3;471(7336):110-4
pubmed: 21368834
Proc Natl Acad Sci U S A. 2019 Dec 3;116(49):24881-24891
pubmed: 31754034
Nat Commun. 2021 Apr 6;12(1):2043
pubmed: 33824312
J Clin Invest. 2012 Mar;122(3):859-72
pubmed: 22307329
J Exp Med. 2007 Aug 6;204(8):1813-24
pubmed: 17646409
Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):9085-90
pubmed: 15150404
Cell Div. 2007 Feb 13;2:7
pubmed: 17298674
Biochem J. 2010 Nov 15;432(1):77-87
pubmed: 20815813
Database (Oxford). 2017 Jan 6;2017:
pubmed: 28062517
Cancer Lett. 2019 Jun 1;451:100-109
pubmed: 30851422
Cancer Sci. 2011 Apr;102(4):749-55
pubmed: 21205095
Gastroenterology. 2010 Sep;139(3):929-41
pubmed: 20638938
Proc Natl Acad Sci U S A. 2018 Aug 7;115(32):8155-8160
pubmed: 29987021
Cancer Lett. 2017 Jan 1;384:27-38
pubmed: 27746162
J Biol Chem. 2021 Jan-Jun;296:100233
pubmed: 33376136
Nat Cell Biol. 2009 Apr;11(4):409-19
pubmed: 19287380
Cell Mol Life Sci. 2020 Jul;77(13):2621-2639
pubmed: 31605148
Biochem Biophys Res Commun. 2006 Nov 10;350(1):114-9
pubmed: 16989775
J Cell Sci. 2012 Feb 15;125(Pt 4):981-92
pubmed: 22399798
Cell Rep. 2021 Mar 30;34(13):108905
pubmed: 33789105
Cell Death Differ. 2021 May;28(5):1563-1578
pubmed: 33268814
Cell. 2013 Jun 20;153(7):1552-66
pubmed: 23791182
Cell Death Differ. 2020 Feb;27(2):420-433
pubmed: 31186535
Cell. 2003 Jan 24;112(2):243-56
pubmed: 12553912
Nat Rev Cancer. 2008 Feb;8(2):83-93
pubmed: 18094723
Front Oncol. 2022 Apr 19;12:880077
pubmed: 35515121
PLoS Pathog. 2015 Sep 25;11(9):e1005179
pubmed: 26407194
Cell Signal. 2018 Jun;46:15-22
pubmed: 29474981
Cell Death Differ. 2022 Jan;29(1):105-117
pubmed: 34363019
Mol Cell. 2016 Nov 3;64(3):493-506
pubmed: 27773673
J Cell Sci. 2011 Jan 1;124(Pt 1):100-12
pubmed: 21147854
Mol Cell. 2016 Feb 4;61(3):419-433
pubmed: 26774286
Cancer Cell. 2005 Jul;8(1):25-33
pubmed: 16023596
Mol Cancer. 2018 Aug 7;17(1):115
pubmed: 30086763
Science. 2008 Sep 12;321(5895):1499-502
pubmed: 18787170
J Biol Chem. 2004 Mar 5;279(10):9417-23
pubmed: 14672936
Nature. 2011 Mar 3;471(7336):104-9
pubmed: 21368833
Cell Death Differ. 2020 Feb;27(2):758-772
pubmed: 31285543
Cell. 2018 Apr 5;173(2):291-304.e6
pubmed: 29625048
Genes Dis. 2019 Jul 24;6(4):359-371
pubmed: 31832515
Cancer Lett. 2013 Oct 10;339(2):214-25
pubmed: 23791882
Science. 2001 Oct 5;294(5540):173-7
pubmed: 11533444
J Mol Cell Biol. 2012 Oct;4(5):316-30
pubmed: 22878263
Cell Rep. 2014 Nov 6;9(3):1099-109
pubmed: 25437563
FEBS J. 2009 Nov;276(21):6324-37
pubmed: 19796173
Curr Biol. 2004 Oct 26;14(20):1852-7
pubmed: 15498494
Mol Cell Biol. 2013 Sep;33(18):3627-43
pubmed: 23858059
Protein Cell. 2011 Mar;2(3):202-14
pubmed: 21468892

Auteurs

Rafael Jiménez-Izquierdo (R)

Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain.
Departamento de Biología Celular, Fisiología e Inmunología, Universidad de Córdoba, Córdoba, Spain.
Hospital Universitario Reina Sofía, Córdoba, Spain.

Rosario Morrugares (R)

Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain.
Departamento de Biología Celular, Fisiología e Inmunología, Universidad de Córdoba, Córdoba, Spain.
Hospital Universitario Reina Sofía, Córdoba, Spain.

Lucía Suanes-Cobos (L)

Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain.
Departamento de Biología Celular, Fisiología e Inmunología, Universidad de Córdoba, Córdoba, Spain.
Hospital Universitario Reina Sofía, Córdoba, Spain.

Alejandro Correa-Sáez (A)

Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain.
Departamento de Biología Celular, Fisiología e Inmunología, Universidad de Córdoba, Córdoba, Spain.
Hospital Universitario Reina Sofía, Córdoba, Spain.

Martín Garrido-Rodríguez (M)

Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain.
Departamento de Biología Celular, Fisiología e Inmunología, Universidad de Córdoba, Córdoba, Spain.
Hospital Universitario Reina Sofía, Córdoba, Spain.

Laura Cerero-Tejero (L)

Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain.
Departamento de Biología Celular, Fisiología e Inmunología, Universidad de Córdoba, Córdoba, Spain.
Hospital Universitario Reina Sofía, Córdoba, Spain.

Omar M Khan (OM)

Hamad Bin Khalifa University, College of Health and Life Sciences Qatar Foundation, Education City, Doha, Qatar.

Susana de la Luna (S)

Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology (BIST), 08003, Barcelona, Spain.
Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Barcelona, Spain.
Universitat Pompeu Fabra (UPF), 08003, Barcelona, Spain.
Institució Catalana de Recerca i Estudis Avançats (ICREA), 08010, Barcelona, Spain.

Rocío Sancho (R)

Centre for Stem Cells and Regenerative Medicine, King's College London, London, SE10 9RT, UK.
Department of Medicine III, University Hospital Carl Gustav Carus, Dresden, Germany.

Marco A Calzado (MA)

Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain. mcalzado@uco.es.
Departamento de Biología Celular, Fisiología e Inmunología, Universidad de Córdoba, Córdoba, Spain. mcalzado@uco.es.
Hospital Universitario Reina Sofía, Córdoba, Spain. mcalzado@uco.es.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH